Business Wire

PSE

Share
SCG Chemicals Company chooses gPROMS modelling for digital design and operations

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations.

SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants.

Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables us to discover and develop new products – for example, new-generation polyethylene – and accelerate their time to market”.

PSE’s gPROMS is widely used throughout the chemicals, energy, petrochemical, food and pharmaceuticals sectors to accelerate innovation and optimise existing operations. Its key advantages are the ability to represent complex processes to a high degree of predictive accuracy using high-fidelity multi-scale models. These can then be used in large-scale process and plant optimisation to maximise economics, and for systematic exploration of the decision space to reduce risk and uncertainty. The new gPROMS Digital Applications Platform now makes it possible also to implement high-fidelity models online for monitoring, forecasting and optimisation, to generate value from day to day.

Says Mr Surachate Chalothorn, SCG’s Process Technology Director, “We apply modelling in three main areas: Operational Excellence, for process optimisation and debottlenecking; in new product development, in order to speed up development and reduce risks in plant trials; and in technology development, to provide a virtual lab for pilot testing.”

James Marriott, head of PSE’s Energy & Chemicals division, said “we are very pleased to be working with innovators like SCG, where the next-generation modelling capabilities that we have to offer can really make a difference.”

For Editors

‘About’ information: www.psenterprise.com/news/pr190322

Contact:

Kate Burness +44-20-8563-0888 k.burness@psenterprise.com

Link:

ClickThru

Social Media:

https://www.facebook.com//Process-Systems-Enterprise-Limited-PSE-194030330653358/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest Launches Professional Services to Elevate Quality Engineering Excellence20.9.2024 17:00:00 CEST | Press release

LambdaTest introduces AI-powered Professional Services to enhance test coverage, optimize scripts, and streamline quality engineering for businesses globally. LambdaTest, a leading cloud-based unified testing platform, officially introduced its Professional Services, designed to transform how organizations achieve quality engineering excellence. This service offers a comprehensive suite of end-to-end testing solutions, powered by AI-driven technology, ensuring maximum test coverage, optimized test scripts, and seamless framework migrations. The newly launched services address key challenges enterprises face today—enhancing testing efficiency, increasing coverage, and reducing bottlenecks in QA. LambdaTest Professional Services also offers tailored test suite development, ensuring that organizations can craft custom solutions suited to their specific needs, while ongoing efficiency maintenance ensures long-term performance and quality. With flexible pricing plans that scale as per busin

Alvaria’s Workforce Enterprise Suite Becomes Aspect20.9.2024 15:00:00 CEST | Press release

New era of growth to be led by newly appointed Chief Executive Officer, Darryl Kelly Alvaria, a pioneer in workforce management and contact center customer experience technology, servicing large global enterprises and rapidly growing consumer brands, announced the rebirth of Aspect in response to accelerated company growth and a demand for more complex tools to support hybrid, remote and in-person workforces. Aspect encapsulates Alvaria’s Enterprise Workforce Suite and will operate as an Alvaria-owned subsidiary. Aspect returns to the brand portfolio with a modern and innovative suite of products, including their new next-generation platform, WorkforceOS, powered by predictive analytics and a mission to humanize the service economy. Aspect has a rich history of innovation and leadership in the contact center space, having pioneered the world’s first Automatic Call Distribution (ACD) and the first Workforce Management Software for contact centers. Alvaria has named Darryl Kelly as Chief

Adtran’s Coherent 100ZR and FSP 3000 OLS to play key role in OIF’s ECOC open interoperability showcase20.9.2024 14:00:00 CEST | Press release

News summary: Adtran FSP 3000 open optical line system facilitates transport of coherent 100ZR and 400G OpenZR+ interfaces in OIF multi-vendor demo Demo spanning nearly 300km also features Adtran’s Coherent 100ZR QSFP28 pluggable transceiver for cost-effective, low-power 100G transport Collaboration with leading industry players highlights Adtran’s role in driving open, scalable optical networking solutions Adtran today announced its key role in the Optical Internetworking Forum’s (OIF) demonstration of open, multi-vendor networking at the European Conference on Optical Communication (ECOC) 2024. At the center of the showcase are Adtran’s Coherent 100ZR QSFP28 pluggable module and its FSP 3000 open optical line system (OLS), which enables the transport of a wide range of data rates, including 100ZR and 400Gbit/s OpenZR+, as featured in this demo. Incorporating 100Gbit/s to 800Gbit/s coherent pluggable transceivers and various OLS technologies from multiple vendors, the demo showcases a

Matchday Champions, a New Class of Mobile Football Game Now Available Worldwide; Kicks off With In-Game Event Hosted by Soccer Superstar Alexia Putellas and Mega Influencer Celine Dept20.9.2024 13:00:00 CEST | Press release

First-of-its-Kind Free-to-Play, Card-Based, AI-Powered Soccer Simulation Game is Backed by Lionel Messi’s Play Time, Officially Licensed by FIFA and FIFPRO Matchday, the developer of innovative mobile games for football’s five billion fans, has debuted its newest title, Matchday Champions. Today, the game is in early access globally, and it is celebrating with the limited-time “Copa Alexia x Céline,” a one-of-a-kind in-game tournament hosted by Spanish football World Cup Champion Alexia Putellas, and the immensely popular Belgian influencer Celine Dept. Backed by Lionel Messi’s Play Time fund, Alexia Putellas, and other industry legends in sports and games, Matchday Champions is a one-of-its-kind experience. The game allows players to collect, craft and manage their own dream squad made up of both men's and women's players. It delivers the excitement of football using a cutting edge narrative creation engine, ensuring no two matches are ever the same. More than two million people have

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy20.9.2024 10:12:00 CEST | Press release

Rare diseases research provides insights into auto-immune diseases and Psoriasis. Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920153092/en/ The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye